Erectile Dysfunction - Pipeline Review, Q4 2010

Global Markets Direct, December 2010, Pages: 59

Erectile Dysfunction - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Erectile Dysfunction Pipeline Review, Q4 2010”, provides an overview of the Erectile Dysfunction therapeutic pipeline. This report provides information on the therapeutic development for Erectile Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Erectile Dysfunction. “Erectile Dysfunction-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Erectile Dysfunction.
- A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Erectile Dysfunction pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Erectile Dysfunction.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Erectile Dysfunction pipeline depth and focus of Erectile Dysfunction therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Erectile Dysfunction Overview
Therapeutics Development
An Overview of Pipeline Products for Erectile Dysfunction
Erectile Dysfunction Therapeutics under Development by Companies
Erectile Dysfunction Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Erectile Dysfunction Therapeutics Development
Eli Lilly and Company
Vectura Group plc
Chong Kun Dang Pharmaceutical
Dong-A Pharmaceutical Co., Ltd.
Pfizer Inc.
VIVUS, Inc.
Bayer AG
NovaDel Pharma, Inc.
Palatin Technologies, Inc.
Plethora Solutions Holdings plc
Rexahn Pharmaceuticals, Inc.
Fabre-Kramer Pharmaceuticals, Inc.
Quatrx Pharmaceutical Company
Ion Channel Innovations, LLC
Universities/Institutes Involved in Erectile Dysfunction Therapeutics Development
Erectile Dysfunction Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Alfuzosin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Androgel + Tadalafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avanafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DA-8159 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Invicorp - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SK3530 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vitaros - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Fluvastatin Sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Folic Acid + Tadalafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Simvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Viagra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zydena - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Erectile Dysfunction - Featured News
Dec 06, 2010: VIVUS Announces Positive Results From Long-Term Phase III Study Of Avanafil In Erectile Dysfunction
Nov 15, 2010: Apricus Biosciences Receives Canadian Approval For Vitaros As First Line Therapy For Erectile Dysfunction
Oct 15, 2010: NovaDel Reports Positive Data From Pilot Pharmacokinetic Study Comparing Duromist To Viagra Tablet
Sep 02, 2010: Palatin Technologies Completes First Cohort Dosing Study Of Bremelanotide For The Treatment Of Sexual Dysfunction
Aug 17, 2010: Palatin Announces Positive Safety Results From Phase I Subcutaneous Bremelanotide Trial In Men
Jun 24, 2010: Nexmed Receives First Patent For Vitaros In Japan
Jun 23, 2010: NexMed Receives Screening Acceptance Letter From Health Canada For Vitaros
Jun 10, 2010: Nexmed Provides Update On Canadian Filing For Vitaros
Jun 07, 2010: VIVUS Announces Positive Results From Phase III Study Of Avanafil In Diabetics With Erectile Dysfunction
Jun 01, 2010: VIVUS Announces Positive Results From Phase III Study Of Avanafil In Erectile Dysfunction
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Erectile Dysfunction – Pipeline Review, H1 2013
• Global Erectile Dysfunction Drug Pipeline Capsule - 2012
• Men's Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth
• The World Market For Sexual Disorders, 2005-2012: Traversing New Frontiers in Sexual Chemistry
• Stakeholder Opinions: Sexual Dysfunction - The quest for the new Viagra continues
• Premature Ejaculation – Pipeline Review, H1 2013
• Nitric Oxide - Therapeutics, Markets and Companies
• Antiageing and Life Enhancement Pharmacotherapeutics: Rejuvenating Drug Markets To 2012 and Beyond
• Textbook of Erectile Dysfunction. Edition No. 2
• Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms (Event Driven)